OncoTargets and therapy最新文献

{"title":"Thyroid Gland as a Metastatic Site for Hepatocellular Carcinoma: A Rare Case Report.","authors":"Yang-Lu Ge, Shui-Quan Jin, Lv-Zhou Han, Xiang Zhang","doi":"10.2147/OTT.S481613","DOIUrl":"10.2147/OTT.S481613","url":null,"abstract":"<p><strong>Background: </strong>Thyroid gland metastasis from distant primary tumors is uncommon, with liver cancer being a particularly rare source. This case report describes the clinical challenges and diagnostic journey of a thyroid mass in a patient with chronic hepatitis B, liver cirrhosis, and hepatocellular carcinoma, underscoring the rarity and complexity of such metastatic relationships.</p><p><strong>Case presentation: </strong>A 63-year-old male with a long-standing history of hepatitis B-related liver cirrhosis and a recent diagnosis of hepatocellular carcinoma presented with a rapidly enlarging painful right-sided thyroid mass associated with swelling but no systemic symptoms such as fever or dysphonia. This prompted a thorough diagnostic workup. Enhanced neck scans indicated a mass potentially originating from the thyroid with tracheal compression, yet crucially, there was no evidence of lung involvement based on the chest CT. Despite the rarity of liver-to-thyroid metastasis, the patient's multifaceted medical history warranted a broad differential diagnosis.</p><p><strong>Intervention and outcome: </strong>Surgical intervention included a right-sided thyroidectomy and partial left thyroidectomy under general anesthesia. Histopathological examination unexpectedly confirmed the presence of metastatic thyroid cancer originating from the primary liver tumor. This led to further extensive surgical management, including lymph node dissection in the central neck area. The postoperative regimen was adapted to include thyroid hormone replacement and ongoing treatment for hepatocellular carcinoma. The patient's postoperative recovery was closely monitored, reflecting stable disease with no immediate complications.</p><p><strong>Conclusion: </strong>This case highlights the clinical rarity and diagnostic challenges of liver cancer metastasizing to the thyroid. It emphasizes the need for vigilance in patients with known primary malignancies, especially hepatocellular carcinoma, presenting with new thyroid abnormalities. This advocates for a comprehensive diagnostic approach in such atypical presentations.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"1033-1039"},"PeriodicalIF":2.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of miR-10a-3p in Non-Small Cell Lung Cancer Patients.","authors":"Julija Simiene, Linas Kunigenas, Rimvile Prokarenkaite, Daiva Dabkeviciene, Egle Strainiene, Vaidotas Stankevicius, Saulius Cicenas, Kestutis Suziedelis","doi":"10.2147/OTT.S475644","DOIUrl":"10.2147/OTT.S475644","url":null,"abstract":"<p><strong>Purpose: </strong>Poor lung cancer patients' outcomes and survival rates demand the discovery of new biomarkers for the specific, significant, and less invasive detection of non-small cell lung cancer (NSCLC) progression. The present study aimed to investigate the potential of miRNA expression as biomarkers in NSCLC utilizing a preclinical cell culture setup based on screening of miRNAs in NSCLC cells grown in 3D cell culture.</p><p><strong>Patients and methods: </strong>The study was performed using lung cancer cell lines, varying in different levels of aggressiveness: NCI-H1299, A549, Calu-1, and NCI-H23, as well as noncancerous bronchial epithelial cell line HBEC3, which were grown in 3D cell culture. Total RNA from all cell lines was extracted and small RNA libraries were prepared and sequenced using the Illumina NGS platform. The expression of 8 differentially expressed miRNAs was further validated in 89 paired tissue specimens and plasma samples obtained from NSCLC patients. Statistical analysis was performed to determine whether miRNA expression and clinicopathological characteristics of NSCLC patients could be considered as independent factors significantly influencing PFS or OS.</p><p><strong>Results: </strong>Differentially expressed miRNAs, including let-7d-3p, miR-10a-3p, miR-28-3p, miR-28-5p, miR-100-3p, miR-182-5p, miR-190a-5p, and miR-340-5p, were identified through next-generation sequencing in NSCLC cell lines with varying levels of aggressiveness. Validation of patient samples, including tumor and plasma specimens, revealed that out of the 8 investigated miRNAs, only plasma miR-10a-3p showed a significant increase, which was associated with significantly extended progression-free survival (PFS) (p=0.009). Furthermore, miR-10a-3p in plasma emerged as a statistically significant prognostic variable for NSCLC patients' PFS (HR: 0.5, 95% CI: 0.3-0.9, p=0.029).</p><p><strong>Conclusion: </strong>Our findings of screening miRNA expression patterns in NSCLC cells grown in 3D cell culture indicated that the expression level of circulating miR-10a-3p has the potential as a novel non-invasive biomarker to reflect the short-term prognosis of NSCLC patients.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"1017-1032"},"PeriodicalIF":2.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Application of Prostate Specific Membrane Antigen in the Diagnosis and Treatment of Prostate Cancer: Status and Challenge.","authors":"Tongwei Zeng, Yongqiang Xie, Keqiang Chai, Hui Sang","doi":"10.2147/OTT.S485869","DOIUrl":"10.2147/OTT.S485869","url":null,"abstract":"<p><p>In recent years, the incidence of prostate cancer has been increasing globally. Early stage of the disease can obtain a better clinical prognosis from surgery and endocrine therapy. The progression of advanced stage varies significantly between individuals, with some patients developing metastatic castration-resistant prostate cancer after standardized treatment. Therefore, staging of prostate cancer by accurate imaging is particularly important for the clinical management of patients. Simultaneously, the development of targeted therapy is also urgent for the treatment of advanced prostate cancer. Prostate specific membrane antigen as a prostate specific target has been widely used in the diagnosis and treatment of prostate cancer. This review summarizes the latest research progress of targeted prostate specific membrane antigen in the diagnosis and treatment of prostate cancer in detail, analyzes their value and challenges.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"991-1015"},"PeriodicalIF":2.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11573878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of Action of HSP110 and Its Cognate Family Members in Carcinogenesis.","authors":"Rongqi Guo, Rui Wang, Weisong Zhang, Yangyang Li, Yihao Wang, Hao Wang, Xia Li, Jianxiang Song","doi":"10.2147/OTT.S496403","DOIUrl":"10.2147/OTT.S496403","url":null,"abstract":"<p><p>Tumors, as chronic malignant diseases that account for about 20% of all deaths worldwide, are the number one threat to human health. Until now there is no reliable treatment for most types of tumors. Tumorigenesis and cellular carcinogenesis remain difficult challenges due to their complex etiology and unknown mechanisms. As stress process regulating molecules and protein folding promoters, heat shock proteins (HSPs) play an important role in cancer development. Most studies have shown that HSPs are one of the major anticancer drug targets. HSPs are not only modulators of the cellular stress response, but are also closely associated with tumor initiation, progression, and drug resistance, so understanding the mechanism of the HSP family involved in cellular carcinogenesis is an important part of understanding tumorigenesis and enabling anticancer drug development. In this review, we discuss the functions and mechanisms of key members of the HSP family (HSP70, HSP90, and HSP110) in participating in the process of tumorigenesis and cell carcinogenesis, and look forward to the prospect of key members of the HSP family in targeted cancer therapy.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"977-989"},"PeriodicalIF":2.7,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management and Future Therapeutic Perspectives of Classic Kaposi's Sarcoma: An Evidence-Based Review.","authors":"Nerina Denaro, Alice Indini, Lucia Brambilla, Angelo Valerio Marzano, Ornella Garrone, Athanasia Tourlaki","doi":"10.2147/OTT.S468787","DOIUrl":"https://doi.org/10.2147/OTT.S468787","url":null,"abstract":"<p><strong>Background: </strong>Kaposi sarcoma (KS) is a cutaneous neoplasm of endothelial origin. The causative agent is the human herpes virus-8 (HHV-8) which, combined with an immune system impairment, causes cell proliferation. To date, high-quality evidence and treatment recommendations for the management of KS are confined to the acquired immune deficiency syndrome (AIDS)-related KS, while the clinical approach to the treatment of classic KS (CKS) is based on small retrospective case series and the experience of clinicians in selected referral centers.</p><p><strong>Materials and methods: </strong>A search of the English literature was conducted through PubMed/MEDLINE databases for studies regarding CKS diagnosis, staging, and treatment, published between January 1990 and September 2023.</p><p><strong>Results: </strong>Overall, 122 out of 565 articles were selected. Based on the results of this literature review, we proposed indications regarding the recommended flow chart for diagnosis, staging, and follow-up of patients with CKS. We assess available evidences regarding topic, locoregional, and systemic treatments of CKS. We also provide a focus on novel treatment strategies and therapeutic approaches currently under evaluation in clinical trials.</p><p><strong>Conclusion: </strong>CKS is a rare disease and its management requires a multidisciplinary assessment. Treatment in referral centers and enrolment in clinical trials might impact on outcomes.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"961-976"},"PeriodicalIF":2.7,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma COL10A1 Level, a Potential Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma.","authors":"Tianlei Wang, Xinrui Bao, Fang Yang, Shenbin Pan, Ke Xu, Tao Ren","doi":"10.2147/OTT.S474540","DOIUrl":"https://doi.org/10.2147/OTT.S474540","url":null,"abstract":"<p><strong>Background: </strong>COL10A1 expression was up-regulated and could promote tumor development in pancreatic cancer. As a secreted protein, plasma COL10A1 level was proven to have certain diagnostic efficacy in gastric cancer, breast cancer, and colorectal cancer. It is still unknown whether it has a biomarker role for pancreatic cancer.</p><p><strong>Aim: </strong>To explore and analyze the diagnostic and prognostic value of plasma COL10A1 level in pancreatic ductal adenocarcinoma (PDAC).</p><p><strong>Method: </strong>The RNA-seq dataset of PDAC from The Cancer Genome Atlas (TCGA) and six expression profiling microarray datasets from Gene Expression Omnibus (GEO) were downloaded to analyze the expression of COL10A1 in tissues. Thirty-six patients with PDAC and eighteen healthy volunteers were enrolled to measure COL10A1 levels in tissues and plasmas, and the relationship between clinical characteristics and the COL10A1 levels was analyzed. The diagnostic and prognostic efficacy of plasma COL10A1 levels were calculated.</p><p><strong>Results: </strong>Aspects of COL10A1 expression level in tissues, COL10A1 expression was significantly higher in PDAC tissue than adjacent normal tissue. The expression of COL10A1 was correlated with T, M, and AJCC stages. Patients with high COL10A1 expression had worse recurrence-free survival (RFS) and overall survival (OS) than those with low expression. Aspects of COL10A1 expression levels in plasma, its diagnostic area under the curve (AUC) for PDAC was 0.926 (95% CI 0.853-0.999), diagnostic sensitivity was 81% (95% CI 64-92%), and specificity was 100% (95% CI 81-100%). The time-dependent AUCs at 1-year and 3-year were 0.71 (95% CI 0.51-0.90) and 0.74 (95% CI 0.48-1.00), respectively.</p><p><strong>Conclusion: </strong>In PDAC, plasma COL10A1 levels showed certain diagnostic and prognostic efficacy. COL10A1 may be a diagnostic and prognostic biomarker for PDAC and play a role in liquid biopsy of this disease.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"949-959"},"PeriodicalIF":2.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilizing Saliva Metabolomics for Diagnosing Gastric Cancer and Exploring the Changes in Saliva Metabolites After Surgery.","authors":"Zhenhua Dong, Qirui Chen, Dingliang Zhao, Shaopeng Zhang, Kai Yu, Gaojun Wang, Daguang Wang","doi":"10.2147/OTT.S482767","DOIUrl":"https://doi.org/10.2147/OTT.S482767","url":null,"abstract":"<p><strong>Purpose: </strong>Gastric cancer (GC) is a disease with high prevalence and mortality, but we lack convenient and accurate methods to screen for this disease. Thus, we aimed to search for some salivary biomarkers and explore changes in metabolites in patients' saliva after radical gastrectomy.</p><p><strong>Patients and methods: </strong>A total of 152 subjects were divided into three groups (healthy group, GC group, and one-week postoperative group). After simple processing, saliva samples were analyzed by liquid chromatography-mass spectrometry. First, we used total ion chromatography and principal component analysis to determine the metabolite profiles. Next, <i>t</i>-test, partial least squares discriminant analysis, support vector machine, and receiver operating characteristics curve analysis were performed to identify biomarkers. Then, Fisher discriminant analysis and hierarchical clustering analysis were performed to determine the discriminating ability of biomarkers. Finally, we established a generalized linear model to predict GC based on biomarkers, and used bootstrapping for internal validation.</p><p><strong>Results: </strong>Between the healthy and GC groups, we identified four biomarkers: lactic acid, kynurenic acid, 3-hydroxystachydrine, and S-(1,2,2-trichlorovinyl)-L-cysteine. We used stepwise regression to select five metabolites and develop a model with areas under the curve equal to 0.973 in the training dataset and 0.924 in the validation dataset. Between the GC and one-week postoperative groups, we found two differential metabolites: 19-hydroxyprostaglandin E₂ and DG (14:0/0:0/18:2n6).</p><p><strong>Conclusion: </strong>Differential metabolites were observed among the three groups. GC could be initially diagnosed on the basis of detection of these biomarkers. Moreover, changes in salivary metabolites in postoperative patients could provide important insights for basic studies.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"933-948"},"PeriodicalIF":2.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrapulmonary Biphasic Mesothelioma Misdiagnosed as Adenocarcinoma: Case Report and a Potential Diagnostic Pitfall.","authors":"Wenfeng Xu, XingYan Zhu, Hao Tang, Qijian Ying, Yujuan Xu, Deyu Guo","doi":"10.2147/OTT.S477916","DOIUrl":"https://doi.org/10.2147/OTT.S477916","url":null,"abstract":"<p><strong>Background: </strong>Mesothelioma is an uncommon malignant tumor with variable clinical presentations, radiological features, and morphological patterns. Mesothelioma with predominantly intrapulmonary growth presents with an insidious onset, similar radiological and even morphological features to lung cancer, and poses a diagnostic pitfall.</p><p><strong>Case presentation: </strong>Herein, we reported a 53-year-old female with biphasic mesothelioma misdiagnosed as poorly differentiated adenocarcinoma with focal sarcomatoid carcinoma. Computed tomography (CT) scan of the chest at the first visit revealed a solid lobulated nodule in the basal segment of the lower lobe of the right lung, which was suspicious of lung cancer. Microscopically, the tumor was composed of epithelioid and spindle cells, both of which were diffusely and strongly positive for CK7, and negative for TTF-1, Napsin A, P40, Melan A, S-100, SMA, and CD34. It was originally misdiagnosed as poorly differentiated adenocarcinoma with focal sarcomatoid carcinoma at initial presentation. Until her second admission with the discovery of a nodule in the right diaphragmatic angle, the peculiar location and biphasic component reminded us of biphasic mesothelioma. Immunohistochemically, tumor cells in both pulmonary and diaphragmatic nodules were positive for calretinin, D2-40, and WT-1, but negative for BerEP4 and MOC31. The patient was treated with a chemotherapy regimen of pemetrexed and carboplatin. After 11 months of follow-up, the patient recovers well without recurrence or metastasis.</p><p><strong>Conclusion: </strong>Mesothelioma with predominantly intrapulmonary growth is extremely rare and poses a diagnostic pitfall. For this entity, subtle morphological features, selection of immunohistochemical markers, and electron microscopy are of great significance for definite diagnosis.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"925-931"},"PeriodicalIF":2.7,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Potential Biomarkers in Papillary Thyroid Carcinoma Based on Proteomics.","authors":"Yu Sun, Jiaxuan Sun, Xiaona Gao, Tiefeng Shi, Maoqing Wang","doi":"10.2147/OTT.S465636","DOIUrl":"https://doi.org/10.2147/OTT.S465636","url":null,"abstract":"<p><strong>Background: </strong>To identify biomarkers of papillary thyroid carcinoma (PTC) and explore the possible pathogenic mechanism.</p><p><strong>Methods: </strong>This study included five patients with PTC. Protein expression of cancer tissues and adjacent normal thyroid tissues from each patient were analyzed by TMT proteomics technology. Differentially expressed proteins were identified, and functional annotation of differentially expressed proteins was performed by bioinformatics and pathway enrichment analysis.</p><p><strong>Results: </strong>A total of 639 differentially expressed proteins were identified, including 278 upregulated and 361 downregulated proteins. Six upregulated proteins were identified as potential specific markers of PTC.</p><p><strong>Conclusion: </strong>Differentially expressed proteins may represent new molecular markers of PTC. These differentially expressed proteins and the related pathways may provide new insights into the pathogenic mechanisms of PTC.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"905-923"},"PeriodicalIF":2.7,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Pan-Cancer Analysis of the Prognostic Role of KLF Transcription Factor 2 (KLF2) in Human Tumors.","authors":"Rong Xu, Yuhan Chen, Shicai Wei, Jun Chen","doi":"10.2147/OTT.S476179","DOIUrl":"10.2147/OTT.S476179","url":null,"abstract":"<p><strong>Background: </strong>KLF2 is a transcription factor expressed early in mammalian development that plays a role in many processes of development and disease. Recently, increasing studies revealed that KLF2 plays a key role in the occurrence and progression of cancer.</p><p><strong>Purpose: </strong>The aim of this study was to explore the role of KLF2 in various tumor types using the Cancer Genome Atlas dataset.</p><p><strong>Methods: </strong>Here, we set out to explore the role of KLF2 in 33 tumor types using TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus) dataset, Human Protein Atlas (HPA), UALCAN database, CancerSEA, GSCALite and several bioinformatic tools. Furthermore, we also performed immunohistochemistry and qPCR to further validate the role of KLF2 in multiple cancers and its correlation with prognosis.</p><p><strong>Results: </strong>We found that KLF2 was underexpressed in most tumors and generally predicted poor OS in tumor patients. We found that amplification of KLF2 may be a risk factor for patients with OV (Ovarian serous cystadenocarcinoma). We also analyzed the abundance of checkpoints and markers of specific immune subsets including CD8+ T lymphocytes (T cells), CD4+ T cells, macrophages, and endothelial cells that significantly correlated with the expression level of KLF2 in pan-carcinoma tissues. In some cancers, KLF2 expression levels are positively correlated with gene promoter DNA methylation and drug sensitivity. In addition, we found that KLF2 is involved in single-cell level cell invasion in some cancers. In addition, KLF2 is co-expressed with several intracellular signal transduction genes involved in immune system processes. Immunohistochemistry and qPCR confirmed the low expression of KLF2 in STAD (stomach adenocarcinoma) and renal cancer.</p><p><strong>Conclusion: </strong>Our pan-cancer analysis provides a comprehensive overview of the oncogenic roles of KLF2 in multiple human cancers and can be regarded as a potential prognostic marker and a novel target for cancer immunotherapy.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"887-904"},"PeriodicalIF":2.7,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}